1. The use of a composition comprising (i) long chain polyunsaturated fatty acid (LC-PUFA)； and (ii) at least one selected from the group consisting of (a) a nucleotide and (b) a nucleotide precursor selected from the group consisting of nucleosides, purine bases, pyridine bases, ribose and deoxyribose； to obtain a composition for administration Caesarean section infant for treating and / or preventing infection, diarrhea, intestinal phlegmon, allergies, atopic eczema, asthma, allergic rhinitis and / or allergic conjunctivitis, and / or for improving intestinal maturation, reducing intestinal penetration and / or for treating disorders associated with the intestinal barrier in a specified infant born by caesarean section, and / or to stimulate the development of a healthy intestinal flora and / or reducing intestinal pathogens in said infant born by caesarean section, where the composition is not human breast milk. 2. The use according to claim 1, in which the composition further comprises at least one non-digestible oligosaccharide selected from the group consisting of fructans (including inulin), fructooligosaccharides, non-digestible dextrins, galactooligosaccharide oligosaccharides, xyloligosaccharigosaccharides, arabes (including cyclodextrins and gentio-oligosaccharides), chitooligosaccharides, glucomannooligosaccharides, galactomano-oligosaccharides, mannanoligosaccharides, fuco igosaharidov, galacturonic oligosaccharides, guluronic acid oligosaccharides, oligosaccharides manna1. Применение композиции, содержащей(i) длинноцепочечную полиненасыщенную жирную кислоту (LC-PUFA)； и(ii) по меньшей мере, одно, выбранное из группы, состоящей из (а) нуклеотида и (b) предшественника нуклеотида, выбранного из группы, состоящей из нуклеозидов, пуриновых оснований, пиридиновых оснований, рибозы и дезоксирибозы；для получения композиции для введения младенцу, рожденному посредством кесарева сечения, для лечения и/или профилактики инфекции, диареи, флегмоны кишечника, аллерг
